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Abstract
Background: The National Institutes of Health (NIH) is among the world’s largest investors in biomedical research, with
a mandate to: ‘‘…lengthen life, and reduce the burdens of illness and disability.’’ Its funding decisions have been criticized
as insufficiently focused on disease burden. We hypothesize that modern portfolio theory can create a closer link between
basic research and outcome, and offer insight into basic-science related improvements in public health. We propose
portfolio theory as a systematic framework for making biomedical funding allocation decisions–one that is directly tied to
the risk/reward trade-off of burden-of-disease outcomes.
Methods and Findings: Using data from 1965 to 2007, we provide estimates of the NIH ‘‘efficient frontier’’, the set of
funding allocations across 7 groups of disease-oriented NIH institutes that yield the greatest expected return on investment
for a given level of risk, where return on investment is measured by subsequent impact on U.S. years of life lost (YLL). The
results suggest that NIH may be actively managing its research risk, given that the volatility of its current allocation is 17%
less than that of an equal-allocation portfolio with similar expected returns. The estimated efficient frontier suggests that
further improvements in expected return (89% to 119% vs. current) or reduction in risk (22% to 35% vs. current) are
available holding risk or expected return, respectively, constant, and that 28% to 89% greater decrease in average years-of-
life-lost per unit risk may be achievable. However, these results also reflect the imprecision of YLL as a measure of disease
burden, the noisy statistical link between basic research and YLL, and other known limitations of portfolio theory itself.
Conclusions: Our analysis is intended to serve as a proof-of-concept and starting point for applying quantitative methods to
allocating biomedical research funding that are objective, systematic, transparent, repeatable, and expressly designed to
reduce the burden of disease. By approaching funding decisions in a more analytical fashion, it may be possible to improve
their ultimate outcomes while reducing unintended consequences.
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Introduction
The National Institutes of Health (NIH) is among the world’s
largest and most important investors in biomedical research. Its
stated mission is to ‘‘seek fundamental knowledge about the nature
and behavior of living systems and the application of that
knowledge to enhance health, lengthen life, and reduce the
burdens of illness and disability’’ (http://www.nih.gov/about/
mission.htm). Some have criticized the NIH funding process as not
being sufficiently focused on disease burden [1–3] (further
discussion about criticisms and recommendations for improving
the process of allocating research funds is provided in Text S1 and
Table S1). Even after allowing for extensive private-sector
translational investment, significant funding gaps between disease
states persist [4]. Furthermore, carefully considered changes in
funding may generate dynamic effects that create more ‘‘mouths
to feed’’ [5]. NIH leaders have observed that research is risky,
involving trade-offs among stated criteria, and also unstated
secondary objectives, e.g., actively ‘‘balancing out’’ spending by
other entities [6]. These factors pose challenges to allocating
research funds.
We consider a framework in which biomedical research
allocation decisions are more directly tied to the risk/reward
trade-off of burden-of-disease outcomes. Prioritizing research
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efforts is analogous to managing an investment portfolio: in both
cases, there are competing opportunities to invest limited
resources, and expected returns, risk, correlations, and the cost
of lost opportunities are important factors in determining the
return of those investments.
Financial decisions are commonly made according to portfolio
theory [7], in which the optimal trade-off between risk and reward
among a collection of competing investments–known as the
‘‘efficient frontier’’–is constructed via quadratic optimization, and
a point on this frontier is selected based on an investor’s risk/
reward preferences. Given a measure of ‘‘return on investment’’
(ROI), an ‘‘efficient portfolio’’ is defined to be the investment
allocation that yields the highest expected return for a given and
fixed level of risk (as measured by return volatility), and the locus
of efficient portfolios across all levels of risk is the efficient frontier.
We recast the NIH funding allocation decision as a portfolio-
optimization problem in which the objective is to allocate a fixed
amount of funds across a set of disease groups to maximize the
expected ‘‘return on investment’’ (ROI) for a given level of
volatility. We define ROI as the subsequent improvements in years
of life lost (YLL), and using historical time series data provided by
the NIH (http://www.nih.gov/about/almanac/appropriations/
index.htm) and the Centers for Disease Control (CDC, http://
wonder.cdc.gov/) for each of 7 disease groups, we estimate the
means, variances, and covariances among these time series. These
estimates serve as inputs to the portfolio-optimization problem.
Such an approach provides objective, systematic, transparent, and
repeatable metrics that can incorporate ‘‘real-world’’ constraints,
and yields well-defined optimal risk-sensitive biomedical research
funding allocations expressly designed to reduce the burden of
disease.
Portfolio theory highlights the value of diversification: investing
in multiple securities with imperfectly correlated pay-offs almost
always yields a better reward-to-risk profile than investing in
a single security. For developing this framework, Markowitz
shared the Nobel Memorial Prize in Economic Sciences, and
today portfolio theory is the starting point for investment
management decisions among the largest institutional investors
[8,9]. Recently, portfolio theory has also been proposed as a means
for conducting health care cost-benefit analysis [10–12].
Methods
Funding Data
The NIH has 27 Institutes and Centers, of which we identified
10 with research missions clearly tied to specific disease states, and
which account for $21 billion of funding in 2005 or 74% of the
total. The disease classification scheme used and the procedure for
constructing the appropriation time series are described in greater
detail in Table S2 and Figure S1. Figure 1 depicts NIH
appropriations data in real (2005) dollars from 1965 to 2005,
and summary statistics are provided in Table S3. The National
Institute of Allergies and Infectious Diseases (NIAID) spending has
been split to account for HIV, which is presented separately (see
HIV discussion below).
These Institutes and the basic research they fund have inevitable
overlap and effect beyond their charter; we treat all spending for
any given Institute as being directed toward the corresponding
disease states, and account for spillover effects by considering the
correlations in the lessening of the burden of disease in other
groups. For example, molecular biology funded by the NCI may
be relevant to infectious diseases but, like the entire NCI budget,
would be assumed for modeling purposes to be directed at cancer;
the hypothetical infectious-disease improvement would appear in
the correlation between the decrease in years of life lost for cancer
and that of infectious diseases.
Burden of Disease Data
Because of its simplicity, availability, breadth, and long history,
years of life lost (YLL) was chosen as the measure of burden of
disease to be used in constructing the estimated return on
investment from NIH-funded research (see Text S1 for a discussion
of other possible measures). The CDC Wide-ranging Online Data
for Epidemiologic Research (WONDER) database (http://
wonder.cdc.gov/) was queried for the underlying cause of death
at the Chapter level (except for mental disorders, where dementia
and unspecified psychoses were all placed in CNS for consistency
with CDC coding after 1998) for International Classification of
Diseases (ICD) categories ICD-9 (for 1979–1998) and ICD-10 (for
1999–2007). The two datasets for pre- and post-1998 were joined
into one continuous series, data were stratified into groups by age
at death, and YLL were computed by comparing the midpoint of
the age ranges with the World Health Organization’s (WHO)
year-2000 U.S. life table (http://www.who.int/whosis/en/). Years
of life lost were then tabulated by Chapter annually, and adjusted
for population growth to remove what would otherwise be
a systematic downward bias in realized health improvements.
This process yielded YLL series for 9 distinct disease groups (see
Table S2 for an analysis of HIV separated from other infectious
disease).
Using 2005 as the base year, the raw YLL observations were
adjusted in other years to be comparable to the 2005 population:
YLLt : YLLrawt |
POP2005
POPt
,
POPt : U:S: population in year t:
ð1Þ
The procedure for assembling the YLL time series is summarized
in Figure S2, and the resulting series, both raw and normalized for
population growth, are shown in Figure 2. Summary statistics for
these adjusted YLL series are also reported in Table S3 for the 9
groups (HIV treated separately). The change in burden of disease
was measured by taking first differences. These first differences
were used to compute the ‘‘return on investment’’ on which the
mean-variance optimizations were based (see the ‘‘Methods’’
section below).
Three disease areas required special consideration: HIV, AMS,
and dementia. AMS and HIV have shorter histories, which is
problematic for estimating parameters based on historical returns
that are lagged by typical FDA approval times plus 4 years.
Dementia, including Alzheimer’s disease and unspecified psycho-
ses, was reclassified with the change from ICD-9 to ICD-10 from
mental and behavioral disorders to diseases of the nervous system;
we placed all dementia YLL in the CNS group to avoid
a transition-point artifact at the juncture between ICD-9 and
ICD-10, and then performed a sensitivity analysis with and
without the dementia YLL. Further work could, in a manner
analogous to our treatment of HIV, treat this group of
neurodegenerative conditions as a separate category.
HIV poses a special challenge given its extreme returns after the
introduction of protease inhibitors, which are outliers that are
likely to be non-stationary and would heavily bias the parameter
estimates on which the portfolio optimization is based. To address
this outlier, HIV spending and its corresponding YLL were
omitted from those of other infectious diseases–the component of
NIAID spending directed at HIV was estimated by straight-line
interpolation from published figures, and this HIV spending was
NIH Efficient Frontier
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treated as a separate entity and subtracted from reported NIAID
appropriations; a similar procedure was followed for the
estimation of HIV-related YLL, and WONDER was queried at
the subchapter level to implement this separation.
For completeness, empirical results that include AMS and HIV
data are provided in Text S1, but because of their unique
characteristics, these two groups are omitted from our main
empirical results other than the summary tables.
Applying Portfolio Theory
To apply portfolio theory, the concept of a ‘‘return on
investment’’ (ROI) must first be defined. Although YLL has
already been chosen as the metric by which the impact of research
funding is to be gauged, there are at least two issues in determining
the relation between research expenditures and YLL that must be
considered. The first is whether or not any relation exists between
the two quantities. While the objectives of pure science do not
always include practical applications that impact YLL, the fact
that part of the NIH mission is to ‘‘reduce the burdens of illness
and disability’’ suggests the presumption–at least by the NIH–that
there is indeed a non-trivial relation between NIH-funded
research and burden of disease. For the purposes of this study,
and as a first approximation, we assume that YLL improvements
are proportional to research expenditures. Of course, factors other
than NIH research expenditures also affect YLL, including
research from other domestic and international medical centers
and institutes, spending in the pharmaceutical and biotechnology
industries, public health policy, behavioral patterns, prosperity
level and environmental conditions. Therefore, the YLL/NIH-
funding relation is likely to be noisy, with confounding effects that
may not be easily disentangled. See the Discussion section above
for a more detailed discussion of this assumption and some possible
alternatives.
The second issue is the significant time lag between research
expenditures and observable impact on YLL. For example,
Mosteller [13] cites a lag of 264 years, starting in 1601, for the
adoption of citrus to prevent scurvy by the British merchant
marine. More contemporary examples [14–16] cite lags of 17 to
20 years. We use shorter lags in this study both because of data
limitations (our entire dataset spans only 29 years), and also to
reduce the impact of factors other than research expenditures on
our measure of burden of disease (YLL). Any attempt to optimize
appropriations to achieve YLL-related objectives must take this lag
into account, otherwise the resulting optimized appropriations
may not have the intended effects on subsequent YLL outcomes.
The impact of NIH-funded research on disease burden is likely
to be spread out over several years after this intervening lag, given
the diffusion-like process in which research results are shared in
the scientific community. For simplicity, the same duration (p=5
years) of the diffusion-like impact for all the disease groups was
hypothesized. The lag q for each disease group was estimated by
running linear regressions associating improvements in YLL over
p=5 years with NIH funding q years earlier and real income and
choosing the lag between 9 and 16 years (beyond which data
limitations and other factors make it impossible to distinguish the
impact of research funding from other confounding factors
affecting YLL) that maximizes the R2 and the corresponding lags
are shown in Figure 3.
This procedure is, of course, a crude but systematic heuristic for
relating research funding to YLL outcomes. Alternatives include
using a single fixed lag across all groups, simply assuming
particular values for group-specific lags based on NIH mandates
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Figure 1. Appropriations data. NIH appropriations in real (2005) dollars, categorized by disease group (http://www.nih.gov/about/budget.htm).
doi:10.1371/journal.pone.0034569.g001
NIH Efficient Frontier
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e34569
and experience, computing a time-weighted average YLL for each
group with a weighting scheme corresponding to an assumed or
estimated knowledge-diffusion rate for that group, or constructing
a more accurate YLL return series by tracking individual NIH
grants within each group to determine the specific impact on YLL
(through new drugs, protocols, and other improvements in
morbidity and mortality) from the award dates to the present.
While the choice of lag is critical in determining the characteristics
of the YLL return series and deserves further research, it does not
effect the applicability of the overall analytical framework. While
our procedure is surely imperfect, it is a plausible starting point
from which improvements can be made.
Assuming constant impact of research funding on YLL over the
duration of p years, the measure of the ROI that accrues to funds
allocated in year t is then given by:
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Figure 2. YLL data. Panel (a): Raw YLL categorized by disease group (http://wonder.cdc.gov/). Panel (b): Population-normalized YLL (with base year
of 2005), categorized by disease group. Both panels are based on data from 1979 to 2007.
doi:10.1371/journal.pone.0034569.g002
Figure 3. Return summary statistics. Summary statistics for the ROI of disease groups, in units of years (for the lag length) and per-capita-GDP-
denominated reductions in YLL between years t and t+4 per dollar of research funding in year t–q, based on historical ROI from 1980 to 2003.
doi:10.1371/journal.pone.0034569.g003
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Rtzq :{
1
p
Pp{1
i~0 (YLLtzqzi{YLLtzqzi{1)|GDPtzqzi
Appropriationt
ð2Þ
where the minus sign reflects the focus on decreases in YLL, and
the multiplier GDPtzq is per capita real gross domestic product
(GDP) in year t+q (http://www.bea.gov/national/index.
htm#personal), which is included to convert the numerator to
a dollar-denominated quantity to match the denominator. This
ratio’s units are then comparable to those of typical investment
returns: date- (t+q) dollars of return per date-t dollars of
investment.
Given the definition in equation (2) for the ROI of each of the
disease groups, the ‘‘optimal’’ appropriation of funds among those
groups must be determined, i.e., the appropriation that produces
the best possible aggregate expected return on total research
funding per unit risk. Denote by R:½R1R2   Rn’ the vector of
returns of all n groups for a given appropriation date t (where time
subscripts have been suppressed for notational simplicity), and
denote by m and S the vector of expected returns and the
covariance matrix, respectively. If the weights of the budget
allocation among the groups are v , the ROI for the entire
portfolio of grants, denoted by Rp, is given by Rp~v
0R, and its
expected value and variance are v 0m and v 0Sv , respectively.
The objective function to be optimized is then given by the
expected value minus some multiple of the variance which reflects
risk tolerance, and this quadratic function of v is maximized using
standard quadratic optimization techniques (see Text S1), subject
to the constraint that the weights sum to 1.
In some financial applications, a variation of this optimization
problem is employed in which the objective function is augmented
to include penalty for allocations that deviate from some pre-
specified vector of target weights vo such as a ‘‘benchmark’’
portfolio. Accordingly, we also consider a ‘‘dual-objective’’
optimization problem in which the additional penalty term is
proportional to deviations from existing NIH allocations vNIH,
and the proportionality constant is given by the coefficient c.
When c~0, the augmented objective function reduces to the
single-objective function described above; when it is positive, the
dual-objective function will yield optimal weights that are closer to
vNIH.
Results
Summary Statistics
Summary statistics of the ROI for the period 1980–2003 are
presented in Figure 3. An example of the ROI calculation for HLB
for 1986 when the return was 18.6 is given in Table S4, summary
statistics of the ROI with AMS and HIV groups included are given
in Table S5, and the correlation matrix of the ROIs is given in
Table S7. Large differences in mean ROI for different Institutes
are evident in Figure 3, ranging from small negative values ( e.g., –
1.7 for CNS) to large positive values ( e.g., 9.8 for HLB). Large
differences in standard deviation also exist, ranging from 0.3 for
NMH to 3.8 for CHD, implying important risk/reward tradeoffs
across Institutes.
Negative mean ROIs are counterintuitive–implying that in-
creasing investment is counterproductive to easing the burden of
disease–yet they occur in three disease groups: AID, CNS, and
DDK. There are several reasons for this phenomenon. First, and
foremost, unlike investments in financial assets, there is significant
randomness in the relation between NIH spending and subsequent
impact on YLL. Many factors other than the amount of funding
affect the success or failure of pure and translational research, and
average ROI values reflect the impact of all of those factors. For
example, in the case of CNS–in which the negative return is more
than two standard deviations away from 0–there is a large non-
stationary effect due to the rapid growth of a group of dementias.
A sensitivity analysis confirms that the negative returns are largely
due to the dementia effect as is indicated in sub-panels (c) and (d)
of Figure 4.
A more subtle effect comes from the fact that favorable ROIs in
one area can impart negative bias in other groups, since all deaths
must be assigned to one cause or group. Consider a simple thought
experiment in which only two lethal diseases, A and B, exist. If
a cure for A is discovered, then those who would otherwise have
died of A must necessarily die of B eventually. This yields an
increase in the YLL for B, even if the treatment of B diseases has
not worsened. Similar, if less-extreme, dynamics can emerge with
more disease groups and less-dramatic progress that merely
reduces rather than eliminates the YLL burden of a specific
disease group.
Finally, and perhaps least likely, the dissemination of erroneous
research results [17] could, in principle, increase YLL until the
error is identified and remedied.
Rather than ‘‘correcting’’ these counterintuitive empirical
relations, we view them as important anomalies that deserve
further scrutiny and analysis. In some cases, e.g., CNS, the
anomaly can be traced to a specific external factor that can either
be accepted as legitimate or set aside as an extreme outlier that is
not representative of the true relation between funding and
subsequent YLL. In the latter case, one alternative to using an
empirically estimated mean ROI to compute the efficient frontier
is to impose a Bayesian prior on this parameter (see Text S1 for
details).
To develop intuition for possible patterns between funding
allocation and improvements in YLL, the cumulative sums of these
two variables are plotted in Figure S5 and the eigenvalues and
eigenvectors of the estimated covariance matrices are provided in
Figure S6. These results suggest that dimension-reducing strategies
such as linear factor models may be useful in this domain.
However, without a more detailed understanding of the common
drivers of progress (if any) among the groups, dimension reduction
via principal components or factor analysis may yield misleading
results due to overfitting.
Efficient Frontiers
In Figure 4, efficient frontiers for the single- and dual-objective
(see equation 2 in Text S1) optimization problems are plotted in
mean-standard deviation space for the 7-group cases with and
without taking into account the dementia effect. Figure S4 depicts
the corresponding 9-group frontiers. For each of these frontiers, in
addition to the mean-standard deviation points for the different
disease groups, the corresponding points for the following funding
allocations are also plotted:
(i) historical average NIH allocation for years 1996–2005;
(ii) equal-weighted (1=n) allocation;
(iii) minimum-variance allocation;
(iv) the allocation on the efficient frontier that has the same
mean as the average NIH allocation (the ‘‘NIH-mean’’
allocation);
(v) the allocation on the efficient frontier which has the same
variance as the average NIH allocation (the ‘‘NIH-var’’
allocation);
NIH Efficient Frontier
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(vi) the allocation on the efficient frontier that is 25% of the
distance from the minimum variance allocation to the
maximum expected-return allocation;
(vii) the allocation on the efficient frontier that is 50% of the
distance from the minimum variance allocation to the
maximum expected-return allocation;
(viii) the allocation on the efficient frontier that is 75% of the
distance from the minimum variance allocation to the
maximum expected-return allocation.
The region bounded by the horizontal segment (i–iv), the
vertical segment (i–v), and the efficient frontier (marked ‘‘DP’’) is of
special interest because all portfolios in this region offer lower
variance, higher expected return, or both when compared to the
average NIH allocation, hence from a mean-variance perspective
such allocations are unambiguously preferable. These allocations
are called ‘‘dominating’’ portfolios relative to the average NIH
allocation (i). Figure 5 contains the portfolio weights corresponding
to portfolios depicted in Figure 4, and Figure 6 provides a relative-
performance comparison of these portfolios in terms of their
expected returns, volatilities, and ratios of the two.
Figure 4A shows that a number of the disease groups appear to
be concentrated in a relatively low-risk sector of the risk/reward
universe, which may be evidence of active variance-minimization
strategies by various stakeholders. Further, Figure 6 suggests that
NIH appropriations are lower volatility than the 1=N portfolio,
while returns are maintained.
A sensitivity analysis is conducted by estimating the efficient
frontier with (Figure 4A) and without the dementia effect
(Figure 4C), and the upper and lower panels of Figure 5 contains
the portfolio weights to these two cases.
The top left sub-panel of Figure 5 shows that the single-objective
optimization does yield sparse weights as expected. For example,
the minimum-variance portfolio allocates to only three groups:
58% to NMH, 25% to CNS, and 16% to ONC. By minimizing
variance, irrespective of the mean, this portfolio allocates funding
to groups with least variability in YLL improvements. The
efficient-25% portfolio allocates non-zero weights in four groups
(41% to NMH, 33% to ONC, 13% to HLB, and 13% to CHD),
and yields 26% better expected return with 28% less risk (Figure 6).
With still more emphasis on expected return, the efficient-50%
portfolio gives non-zero weights only to three successful groups:
42% to ONC, 32% to the higher risk, higher expected-return
HLB, and 27% to CHD. This portfolio has 172% higher expected
return but only 27% more risk than the NIH portfolio. The
efficient-75% portfolio gives an even higher weight of 55% to
HLB, 36% to CHD, and 9% to ONC, yielding 318% higher
expected return and 148% more risk, a diminishing risk-adjusted
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Figure 4. Efficient frontiers. Efficient frontiers for (a) all groups except HIV and AMS, c~0; (b) all groups except HIV and AMS, c~5; (c) all groups
except HIV and AMS without the dementia effect, c~0; and (d) all groups except HIV and AMS without the dementia effect, c~5; based on historical
ROI from 1980 to 2003. The region labeled ‘‘DP’’ indicates portfolios that dominate the historical average NIH portfolio.
doi:10.1371/journal.pone.0034569.g004
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expected return as compared to portfolios with lower volatility.
Given the greater emphasis on expected return for this portfolio, it
is not surprising to see HLB getting a bigger role due to its
apparent historical success in reducing YLL. Of course, whether
or not past success is indicative of comparable future success
hinges on the science and associated translational efforts un-
derlying the diseases covered by HLB. This underscores the
importance of incorporating research and clinical insights into the
funding allocation process, especially within a systematic frame-
work such as portfolio theory.
However, the dementia effect may underestimate the perfor-
mance of the CNS disease group, hence the lower panel of Figure 5
reports corresponding optimal-portfolio results without the de-
mentia effect. In the single-objective case, the efficient-50% and
75% portfolios are still sparse, with non-zero weights in 3 groups,
while the lower risk efficient-25% portfolio is less concentrated
with non-zero weights to 4 groups and significant weight (27%) to
the CNS group.
Figure 5 also contains the optimal portfolios for the dual-
objective case (with c~5) in the right sub-panels (see Figure 4B
and 4D). These cases correspond to portfolios that trade off
closeness to the average NIH allocation policy with better risk-
adjusted expected returns. Now we observe that for both upper
and lower sub-panels corresponding to the 7-group with/without
the dementia effect optimization, respectively, the weights are less
concentrated than in the single-objective case. For example, the
minimum-variance portfolio without the dementia effect now
allocates funding to all the groups, with weights ranging from 5%
to 31%. However, even in this case, the efficient-75% portfolio is
still extreme, allocating weights only to HLB, CHD and ONC.
Therefore, special care must be exercised in selecting the
appropriate point on the efficient frontier. We also observe from
the NIH-var or NIH-mean portfolios that slight changes to the
average NIH policy apparently yield superior performance in
mean-standard deviation space (Figure 6 indicates 28% to 89%
relative improvement, depending on the assumptions). Table S6
contains the portfolio weights when the HIV and AMS groups are
included in our analysis.
Discussion
Portfolio theory is a systematic framework for determining
optimal research funding allocations based on historical return on
investment, variance, and correlation between appropriations and
reductions in disease burden. The optimization results suggest that
significant YLL improvements with respect to a mean-variance
criterion may be possible through funding re-allocation. To our
knowledge, this is the first time such an approach has been
empirically implemented in this domain.
Figure 5. Portfolio weights. Benchmark, single- and dual-objective optimal portfolio weights (in percent), based on historical ROI from 1980 to
2003.
doi:10.1371/journal.pone.0034569.g005
Figure 6. Relative performance. Relative volatility (s), expected return (m) and risk-adjusted returns (m/s) for different scenarios (see text) for both
c~0 and 5 compared, including dementia: NIH with uniform allocation, and scenarios with NIH historical performance. A value of 1.00 implies the
same performance, 0.92 implies 8% worse, while 1.12 implies 12% improvement.
doi:10.1371/journal.pone.0034569.g006
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Our method identifies optimal portfolios which, for a given
degree of risk, are efficient in reducing YLL. However, some
optimal allocations may allocate no funds to certain disease groups
(typically those with low expected return and high volatility). While
this may be reasonable from a mean-variance optimization
perspective, it is obviously an extreme and impractical outcome.
A first step toward recognizing the trade-off between reallocation
costs and efficiency is the dual-objective optimization procedure
which penalizes allocations away from a pre-specified ‘‘bench-
mark’’ allocation, e.g., the current NIH policy. This more-
conservative approach increases diversification with less realloca-
tion cost than the single-objective procedure. For instance, in the
dual-objective optimization, the NIH-mean portfolio is relatively
close to the current allocation (see Figure 5), yet the risk-adjusted
returns are 28% higher as seen in Figure 6. The method is also
sufficiently flexible to add further constraints reflecting other policy
goals such as imposing lower or upper bounds on expenditures for
disease groups.
Our findings must be qualified in at least three respects: (1) YLL
as a measure of burden of disease, which is clearly incomplete and
less than ideal; (2) the definition of ROI and the challenges of
relating research expenditures to subsequent outcomes such as
burden of disease; and (3) the known limitations of portfolio theory
from the financial context. Each of these qualifications is discussed
in greater detail in Text S1, and while they can all be addressed to
varying degrees through additional data and analysis, the
empirical conclusions are likely to depend critically on the nature
of their resolution. In this section, we provide a short synopsis of
these qualifications, and also consider other objections to this
framework and directions for future research.
YLL captures only the most extreme form of disease burden;
more refined measures such as disability-adjusted or quality-
adjusted life years are clearly preferable. However, time series
histories for such measures are currently unavailable. Therefore,
YLL is the most natural starting point for gauging the impact of
biomedical research funding, and is directly aligned with the NIH
mission to ‘‘lengthen life’’.
Our definition of ROI can also be challenged as being
imprecise and ad hoc in several respects. NIH funding is typically
focused on basic research rather than translational efforts,
therefore, NIH spending may not be as directly related to
subsequent YLL improvements. We have not accounted for
other expenditures that may also affect YLL, and to the extent
that NIH appropriations are systematically used to complement
private spending [6], the relation between NIH allocations and
YLL improvements may be even noisier. Also, the standard
portfolio-optimization framework implicitly assumes a constant
multiplicative relation between dollars invested today and dollars
returned tomorrow (so that doubling the investment will typically
double the ROI of that investment), whereas the return to
biomedical investments may be non-linear and will likely exhibit
diminishing returns. Furthermore, returns are bounded–the best
we can hope for is a cure, beyond which further improvement is
impossible. In addition, translational research takes time and
significant non-NIH resources, further blurring the relation
between NIH allocations and subsequent changes in YLL.
Finally, other factors may contribute to YLL improvements,
including changes in cultural norms, economic conditions, and
public policy.
While all of these qualifications have merit, they are not
insurmountable obstacles and can likely be addressed through
additional data collection and more sophisticated metrics, perhaps
along the lines of Porter [18] or Lane and Bertuzzi [19].
Moreover, the portfolio-optimization approach provides a useful
conceptual framework for formulating funding allocation decisions
systematically, even if its empirical implications are imprecise.
There are also several limitations of portfolio theory that are
well-known in the financial context (e.g., estimation error,
parameter instability, and exogenous constraints such as non-
negativity restrictions on portfolio weight), all of which can be
addressed to some degree through statistical techniques such as
resampling, Bayesian analysis, and robust optimization [20].
However, one limitation that is unique to biomedical applications
is the fact that portfolio theory is silent on which mean-variance-
optimal portfolio to select. In the financial context, the existence of
a riskless investment (e.g., U.S. Treasury bills) implies that one
unique portfolio on the efficient frontier will be desired by all
investors–the so-called ‘‘tangency’’ portfolio [21] (see Figure S3).
Because there is no analog to a riskless investment in biomedical
research, the notion of a tangency portfolio does not exist in this
context. Therefore, decision makers must first determine society’s
collective preferences for risk and return with respect to changes in
YLL before a unique solution to the portfolio-optimization
problem can be obtained, i.e., they must agree on a societal
‘‘utility function’’ for trading off the risks and rewards of
biomedical research.
This critical step is a pre-requisite to any formal analysis of
funding allocation decisions, and underscores the need for
integration of basic science with biomedical investment perfor-
mance analysis and science policy. Such integration will require
close and ongoing collaboration between scientists and policy-
makers to determine the appropriate parameters for the funding
allocation process, and to incorporate prior information and
qualitative judgments [22] regarding likely research successes,
social priorities, policy objectives and constraints, and hidden
correlations due to non-linear dependencies not captured by the
data. In particular, it is easy to imagine contexts in which
funding objectives can and should change quickly in response to
new environmental threats or public-policy concerns. However,
such pressing needs must be balanced against the disruptions–
which can be severe due to the significant adjustment costs
implicit in biomedical research [23]–caused by large unantici-
pated positive or negative shifts in research funding. Although
the end result of collaborative discussion may fall short of a well-
defined objective function that yields a clear-cut optimal portfolio
allocation, the portfolio-optimization process provides a trans-
parent and rational starting point for such discussions, from
which several insights regarding the complex relation between
research funding and social outcomes are likely to emerge.
These qualifications suggest that portfolio theory cannot be
mechanically applied to historical data to yield actionable optimal
allocations. However, our empirical results should be sufficient
proof-of-concept to motivate additional data collection, empirical
analysis, and research to advance the state of the art in this
application area. Any repeatable and transparent process for
making funding allocation decisions–especially one that involves
criteria other than peer-review-based academic excellence–will,
understandably, be viewed initially with some degree of suspicion
and contempt by the scientific community. But if one of the goals
of biomedical research is to reduce the burden of disease, some
tension between academics and public policy may be unavoidable.
Moreover, in the absence of a common framework for evaluating
the trade-offs between academic excellence and therapeutic
potential, other proposed alternatives such as political earmarking
[24] may be even less palatable from scientific and humanitarian
perspectives.
In an environment of tightening budgets and increasing
oversight of appropriations, portfolio theory offers scientists,
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policymakers, and regulators–all of whom are, in effect, research
portfolio managers–a rational, systematic, transparent, and re-
producible framework in which to explicitly balance expected
benefits against potential risks while accounting for correlation
among multiple research agendas and real-world constraints in
allocating scarce resources. Most funding agencies and scientists
have already been making such trade-offs informally and
heuristically. There may be additional benefits to making such
decisions within an explicit framework based on standardized and
objective metrics.
One of the most significant benefits from adopting such
a framework may be the reduction of uncertainty surrounding
future funding-allocation decisions. This alone would greatly
enhance the ability of funding agencies and scientists to plan for
the future and better manage their respective budgets, research
agendas, and careers. By approaching funding decisions in a more
analytical fashion, it may be possible to improve their ultimate
outcomes while reducing the chances of unintended consequences.
Supporting Information
Figure S1 NIH time series flowchart. Flowchart for the
construction of NIH appropriations time series. ‘‘NIH Approp.’’
denotes NIH appropriations; ‘‘PHS Gaps’’ denotes Institute
funding by the U.S. Public Health Service; ‘‘Complete Approp.’’
denotes the union of these two series; ‘‘FY Change’’ allows for the
change in government fiscal years; ‘‘4Q FY’’ time series refers to
the resulting series in which all years are treated as having four
quarters of three months each; and ‘‘CPI’’ refers to the Consumer
Price Index.
(EPS)
Figure S2 YLL time series flowchart. Flowchart for the
construction of years of life lost (YLL) time series. ‘‘WONDER
Chapter Age Group’’ refers to a query to the CDC WONDER
database at the chapter level, stratified by age group at death; ‘‘US
Pop.’’ is the United States population from census data as
expressed in the WONDER dataset; and ‘‘US GDP’’ denotes U.S.
gross domestic product.
(EPS)
Figure S3 Efficient frontier illustration. Efficient frontier
(blue) in mean-standard deviation space, indifference curves
(green), and optimal portfolio T which is the tangency point of
the efficient frontier and the highest indifference curve achievable
(U1) by a frontier portfolio. Point A corresponds to the minimum-
variance portfolio.
(EPS)
Figure S4 Empirical estimates of NIH efficient fron-
tiers. Efficient frontiers for (a) all groups, c~0; (b) all groups,
c~10; (c) all groups without the Alzheimer effect, c~0; and (d) all
groups without the Alzheimer effect, c~5; based on historical
ROI from 1980 to 2003, except for AMS ROI which is available
only from 1997 to 2007, and HIV ROI which is available only
from 1996 to 2007.
(EPS)
Figure S5 Learning curves. Each of the seven graphs shows
for each of the disease groups (labeled at the top of each graph),
a curve representing the cumulative spending in millions of dollars
along the horizontal axis and the future cumulative change in
millions of years of life lost (YLL) on the vertical, where the offset q
between current spending and future changes in YLL is given in
Figure 3. The cumulative change in YLL covers the years from
1980 to 2007 for all the disease groups. For each group, the
corresponding NIH appropriations are translated back q years.
(EPS)
Figure S6 Eigenvalues and eigenvectors. Cumulative
eigenvalues and eigenvectors of the sample covariance matrix of
annual returns of the 7 NIH groups, based on historical returns
from 1980 to 2003.
(EPS)
Table S1 IoM recommendations. 12 major recommenda-
tions of the 1998 Institute of Medicine panel in four large areas for
improving the process of allocating research funds.
(EPS)
Table S2 ICD mapping. Classification of ICD-9 (1978–1998)
and ICD-10 (1999–2007) Chapters and NIH appropriations by
Institute andCenter to 7 disease groups: oncology (ONC); heart lung
and blood (HLB); digestive, renal and endocrine (DDK); central
nervous system and sensory (CNS) into which we placed dementia
and unspecified psychoses to create comparable series as there was
a clear, ongoing migration noted from NMH to CNS after the
change to ICD-10 in 1999; psychiatric and substance abuse (NMH);
infectious disease, subdivided into estimated HIV (HIV) and other
(AID); maternal, fetal, congenital and pediatric (CHD). The
categories LAB and EXT are omitted from our analysis.
(EPS)
Table S3 Summary statistics for YLL and funding.
Summary statistics for YLL and NIH-appropriations time series
data. YLL data are from 1979 to 2007, except for HIV YLL data
which are only available from 1987 to 2007. NIH-appropriations
data are from 1965 to 2005, except for AMS and HIV
appropriations data which are only available from 1987 to 2005.
(EPS)
Table S4 ROI example. An example of the ROI calculation
for HLB from 1986.
(EPS)
Table S5 Summary statistics for ROI. Summary statistics
for the ROI of disease groups, in units of years (for lag length) and
per-capita-GDP-denominated reductions in YLL between years
t and t+4 per dollar of research funding in year t–q, based on
historical ROI from 1980 to 2003, except for AMS ROI which is
available only from 1997 to 2007, and HIV ROI which is
available only from 1996 to 2007.
(EPS)
Table S6 Portfolio weights for all groups. Single- and
dual-objective optimal portfolio weights (in percent), based on
historical ROI from 1980 to 2003, except for AMS which is
available only from 1997 to 2007, and HIV which is available only
from 1996 to 2007.
(EPS)
Table S7 Seven-group correlation matrix. Correlation
matrix of ROI (in percent), based on historical ROI time series
from 1980 to 2003.
(EPS)
Text S1 Supporting Information. NIH background and
literature review, details of data construction and analysis, the
analytics of traditional and Bayesian portfolio optimization,
additional empirical results, and limitations and qualifications of
our analysis are included in this file.
(PDF)
NIH Efficient Frontier
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e34569
Acknowledgments
We thank Melissa Antman, Ernie Berndt, Stefano Bertuzzi, Martin Brown,
Carole Christian, Charles DeLisi, Anne Fladger, Huybert Groenendaal,
Sushil Gupta, Robert Harriman, Lynn Hudson, Srinivasan Kumar, Eric
Lander, Meaghan Muir, Chris Murray, Luci Roberts, Carl Roth, James
Schuttinga, David Soybel, Narayan Venkatasubramanyan, and Madeleine
Wallace for comments and discussion. The views and opinions expressed in
this article are those of the authors only, and do not necessarily represent
the views and opinions of: the individuals acknowledged above,
AlphaSimplex Group, Brigham and Women’s Hospital, Harvard Medical
School, MIT, or any of their affiliates and employees.
Author Contributions
Conceived and designed the experiments: DB AWL JFW. Performed the
experiments: DB JFW. Analyzed the data: DB AWL JFW. Contributed
reagents/materials/analysis tools: DB AWL JFW. Wrote the paper: DB
AWL JFW. Jointly posed the problem: AWL JFW. Provided the portfolio
optimization framework: AWL DB. Provided medical expertise: JFW.
Provided overall coordination for the project: AWL. Collected the raw
NIH and YLL data: JFW. Jointly cleaned and processed the data: JFW DB.
Reviewed the data: AWL JFW DB. Performed all computations under the
supervision of AWL and JFW: DB. Discussed the results and implications
and contributed original ideas to the project: AWL JFW DB. Prepared the
final draft of the manuscript with contributions and editorial feedback from
DB and JFW: AWL.
References
1. Rangel SJ, Efron B, Moss RL (2002) Recent trends in National Institutes of
Health funding of surgical research. Annals of Surgery 236: 277–287.
2. Johnston SC, Hauser SL (2006) Basic and clinical research: what is the most
appropriate weighting in a public investment portfolio? Annals of Neurology 60:
9A–11A.
3. Istook E (1997) Research funding on major diseases is not proportionate to
taxpayer’s needs. Journal of NIH Research 9: 26–28.
4. Dorsey ER, Thompson JP, Carrasco M, de Roulet J, Vitticore P, et al. (2009)
Financing of U.S. biomedical research and new drug approvals across
therapeutic areas. PLoS ONE 4: e7015.
5. Teitelbaum MS (2008) Structural disequilibria in biomedical research. Science
321: 644–645.
6. Varmus H (1999) Evaluating the burden of disease and spending the research
dollars of the National Institutes of Health. New England Journal of Medicine
340: 1914–1915.
7. Markowitz HM (1952) Portfolio selection. Journal of Finance 7: 77–91.
8. McFarlane FW (1981) Portfolio approach to information systems. Harvard
Business Review 59: 142–150.
9. Chandra S (2003) Regional economy size and the growth/instability frontier:
Evidence from Europe. Journal of Regional Science 43: 95–122.
10. O’Brien BJ, Sculpher MJ (2000) Building uncertainty into cost-effectiveness
rankings: Portfolio risk-return tradeoffs and implications for decision rules.
Medical Care 38: 460–468.
11. Bridges JFB, Stewart M, King MT, van Gool K (2002) Adapting portfolio theory
for the evaluation of multiple investments in health with a multiplicative
extension for treatment synergies. European Journal of Health Economics 3:
47–53.
12. Sendi P, Al MJ, Rutten FFH (2004) Portfolio theory and cost-effectiveness
analysis: A further discussion. Value In Health 7: 595–601.
13. Mosteller F (1981) Innovation and evaluation. Science 211: 881–886.
14. Comroe JH Jr., Dripps RD (1976) Scientific basis for the support of biomedical
science. Science 192: 105–111.
15. Grant J (2000) Evaluating ‘‘payback’’ on biomedical research from papers cited
in clinical guide-lines: applied bibliometric study. BMJ 320: 1107–1111.
16. Hanney S, Frame I, Grant J, Green P, Buxton M (2003) From Bench to Bedside:
Tracing the Payback Forwards from Basic or Early Clinical Research A
Preliminary Exercise and Proposals for a Future Study. Uxbridge, UK: Health
Economics Research Group, Brunel University.
17. Ioannidis JPA (2005) Why most published research findings are false. PLoS
Medicine 2: e124.
18. Porter ME (2010) What is value in health care? New England Journal of
Medicine 363: 2477–2481.
19. Lane J, Bertuzzi S (2011) Measuring the results of science investments. Science
331: 678–680.
20. Bade A, Frahm G, Jaekel U (2009) A general approach to Bayesian portfolio
optimization. Math- ematical Methods of Operations Research 70: 337–356.
21. Sharpe WF (1964) Capital asset prices: a theory of market equilibrium under
conditions of risk. J Finance 19: 425–442.
22. Black N (2009) Health services research: the gradual encroachment of ideas.
Journal of Health Services Research & Policy 14: 120–123.
23. Freeman R, Reenen JV (2009) What if Congress doubled R&D spending on the
physical sciences? Technical Report 931, Center for Economic Performance.
24. Anderson C (1993) A new kind of earmarking. Science 260: 483.
NIH Efficient Frontier
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e34569
